Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Total Liabilities: 2020-2025

Historic Total Liabilities for Janux Therapeutics (JANX) over the last 5 years, with Sep 2025 value amounting to $48.2 million.

  • Janux Therapeutics' Total Liabilities rose 23.89% to $48.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.2 million, marking a year-over-year increase of 23.89%. This contributed to the annual value of $38.7 million for FY2024, which is 7.42% up from last year.
  • Latest data reveals that Janux Therapeutics reported Total Liabilities of $48.2 million as of Q3 2025, which was up 15.62% from $41.7 million recorded in Q2 2025.
  • Janux Therapeutics' 5-year Total Liabilities high stood at $48.2 million for Q3 2025, and its period low was $12.0 million during Q2 2021.
  • Moreover, its 3-year median value for Total Liabilities was $38.7 million (2024), whereas its average is $39.1 million.
  • Per our database at Business Quant, Janux Therapeutics' Total Liabilities skyrocketed by 245.45% in 2022 and then dropped by 20.32% in 2024.
  • Janux Therapeutics' Total Liabilities (Quarterly) stood at $13.5 million in 2021, then spiked by 220.59% to $43.3 million in 2022, then dropped by 16.67% to $36.1 million in 2023, then grew by 7.42% to $38.7 million in 2024, then increased by 23.89% to $48.2 million in 2025.
  • Its Total Liabilities was $48.2 million in Q3 2025, compared to $41.7 million in Q2 2025 and $38.3 million in Q1 2025.